All News

Approval comes from positive results in the MATINEE and METREX phase III trials, with data showing a significant reduction in annual rates of COPD exacerbations among patients.

Insulin delivery technology company Sequel Med Tech announced its future partnership with Abbott’s glucose-ketone sensor, which is currently under development.

A conversation with Micah Cost, PharmD, MS, CAE, CEO of PQA, at PQA 2025.

During Viral Hepatitis Awareness Month, Jeff Goad, PharmD, MPH, joined Over the Counter to discuss hepatitis vaccines and the common trends pharmacists in this space should keep in mind.

The new program aims to reduce costs for patients, with savings estimated at as much as $3600 per year.

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.

A conversation with Kaitlin Bates, PharmD, ARHOME Quality Manager at Arkansas Blue Cross and Blue Shield, at PQA 2025.

Importing prescription drugs from Canada has been met with criticism, such as weakening the pharmaceutical supply chain and posing increased risks to patient safety.

Patients included in the study were aged 6 to 17 years with attention deficit/hyperactivity disorder (ADHD).

Pharmacists can substitute ustekinumab with the biosimilar at the pharmacy level, depending on their state laws.

Researchers investigate annual medication costs for children and determine which of them would qualify for medication therapy management based on CMS thresholds.

Researchers aim to understand how deprescribing interventions impacted changes in inappropriate medication use or total prescription drugs among older, community-dwelling adults.

A conversation with Michael Hegener, PharmD, BCACP, associate professor of Pharmacy at the University of Cincinnati, at PQA 2025.

V116 is noninferior to 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all 12 common serotypes and superior to 9 unique serotypes.

President of the National Foundation for Infectious Diseases, Jeff Goad, PharmD, MPH, discusses how pharmacists can help improve hepatitis A and B vaccine rates across the country.

Approximately 67% of adults in the US know that vaccines do not cause autism in children, declining significantly from 74% in 2021.

In part 2 of our video series with drug market experts Luke Turnock, PhD, and Jenny Markell, we explored social media advertisements for prescription drugs and how they may impact patients.

A conversation with Mitchell Barnett, PharmD, MS, professor of pharmaceutical sciences at Texas A&M University, at PQA 2025.

Researchers estimate the cost-effectiveness of PCV24 in the older adult population compared with the currently accepted pneumococcal vaccine schedules in the US.

Specialty pharmacies help support their continuity of care with practiced disaster response plans.

Researchers wanted to better understand prescribing patterns of pneumococcal vaccines for people living with HIV in a tertiary care hospital.

However, there is no association between cortisol and tau pathology.

Researchers conduct a scoping review to update and determine what the best available options are for treating patients with skin-picking disorder.

Pharmacies face mounting challenges amid increased competition, rising operational costs, and complex reimbursement models.

In children aged 5 to 17 with skin disorders, researchers explore the risk of developing psychosocial comorbidities, sleep disturbances, and common related symptoms.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Jeff Goad, PharmD, MPH, discusses hesitancy for hepatitis vaccines and the necessary advice pharmacists can utilize to help patients manage these misconceptions.

Novavax’s COVID-19 vaccine has been available in the US under emergency use authorization since July 2022.

Researchers conducted a clinical review detailing the intersection of dermatology and suicide, explaining why skin conditions lead to increased risk of poor mental health.

Investigators note that the long-term effects of attention deficit/hyperactivity disorder (ADHD) medication for children remain lacking.